BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36495678)

  • 1. Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma.
    Zajec Ž; Dernovšek J; Distel M; Gobec M; Tomašič T
    Bioorg Chem; 2023 Feb; 131():106311. PubMed ID: 36495678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
    Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
    Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Discovery and Optimisation of a Novel Structural Class of Hsp90 C-Terminal Domain Inhibitors.
    Zajec Ž; Dernovšek J; Gobec M; Tomašič T
    Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
    Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
    Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
    van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
    J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
    Loganathan SN; Tang N; Holler AE; Wang N; Wang J
    Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
    McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
    Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically Engineered Mouse Model in Ewing Sarcoma.
    Tanaka M; Nakamura T
    Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
    Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
    Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
    Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
    Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.